EICHORCondition: Extensive-Stage Small Cell Lung Cancer · Sponsor: Bristol-Myers Squibb
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
This description comes directly from the study's public registry record.
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com · 855-907-3286 · Clinical.Trials@bms.com
First line of the email MUST contain NCT # and Site #.
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria * Participants must have diagnosis of Extensive-Stage Small Cell Lung Cancer (ES-SCLC). * Participants must be Healthy enough to do their normal activities with little or no help based on the ECOG performance scale. * Participants must have at least one tumor that can be measured using special imaging techniques like a CT scan or MRI at a site other than the brain and nervous system Exclusion Criteria * Participants have already received certain types of treatment for extensive stage small cell lung cancer * Participants have certain health conditions, like spread of small cell lung cancer to the brain that are causing symptoms, certain lung diseases, heart diseases, infections, autoimmune diseases, other cancers, or a type of nerve damage called peripheral sensory neuropathy * Other protocol-defined Inclusion/Exclusion criteria apply.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Southern Cancer Center, PC | Daphne, Alabama, United States | Recruiting |
| Local Institution - 0283 | Hot Springs, Arkansas, United States | Completed |
| Florida Cancer Specialists - South | Fort Myers, Florida, United States | Recruiting |
| Mid Florida Hematology and Oncology Center | Orange City, Florida, United States | Recruiting |
| Florida Cancer Specialists - North | St. Petersburg, Florida, United States | Recruiting |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital | Marietta, Georgia, United States | Recruiting |
| Illinois Cancer Care | Peoria, Illinois, United States | Recruiting |
| Local Institution - 0037 | Minneapolis, Minnesota, United States | Withdrawn |
| University of New Mexico Comprehensive Cancer Center | Albuquerque, New Mexico, United States | Recruiting |
| Duke Cancer Institute | Durham, North Carolina, United States | Recruiting |
| Sanford Medical Center | Bismarck, North Dakota, United States | Recruiting |
| Sanford Fargo Medical Center | Fargo, North Dakota, United States | Recruiting |
+ 171 more locations — full list on the registry record.
This study lists sites in the areas below. Each link shows other recruiting studies near that city, from the public registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06646276